2023-05-23 シンガポール国立大学(NUS)
◆シンガポールで行われたコミュニティ研究では、年齢が38歳から91歳までの101人の参加者に、NUSの研究者が2019年に発明したBIXEPSデバイスを使用して週に一度、非常に低いレベルの特許取得済みパルス電磁場(PEMF)に曝露させたところ、12週間後に特に高齢者において、運動能力と体組成が有意に改善された。参加者は磁気筋肉療法を3か月間受けた後、痛みの感覚が軽減されたと報告した。
<関連情報>
- https://news.nus.edu.sg/brief-weekly-magnetic-muscle-therapy-improves-mobility-and-lean-body-mass-in-older-adults/
- https://www.aging-us.com/article/204597/text
週1回の短期磁気筋肉療法は高齢者の運動能力と除脂肪体重を改善する:東南アジアのコミュニティのケーススタディ。 Brief, weekly magnetic muscle therapy improves mobility and lean body mass in older adults: a Southeast Asia community case study
Sharanya Venugobal, Yee Kit Tai, Jorming Goh, Sean Teh1 , Craig Wong, Ivan Goh, Andrea B. Maier, Brian K. Kennedy, Alfredo Franco-Obregón
Aging Published: March 19, 2023
DOI:https://doi.org/10.18632/aging.204597
Abstract
Brief (10 min) weekly exposure to low energy pulsed electromagnetic fields (PEMFs) has been shown to improve human muscle mitochondrial bioenergetics and attenuate systemic lipotoxicity following anterior cruciate ligament surgical reconstruction. Here we present data generated from 101 participants, 62% female, aged 38–91 years, recruited from the QuantumTx Demo Centre in Singapore, wherein 87% of participants (n = 88) presented with pre-existing mobility dysfunction and 13% (n = 13) were healthy volunteers. Participants were recruited if: (i) not pregnant; (ii) above 35 years of age and; (iii) without surgical implants. All participants completed mobility testing, pre- and post- PEMF intervention for 12 weeks, whereas bioelectrical impedance analysis was conducted in a subgroup of 42 and 33 participants at weeks 4 and 8, respectively. Weekly PEMF exposure was associated with significant improvements in mobility (Timed Up and Go, 5 times Sit-to-Stand, and 4m Normal Gait Speed) and body composition (increased skeletal muscle mass and reduced total and visceral fat mass), particularly in the older participants. Perception of pain was also significantly reduced. PEMF therapy may provide a manner to counteract age-associated mobility and metabolic disruptions and merits future investigation in randomized controlled trials to elucidate its clinical benefits in the frail and older adult populations.
